Article History
Received: 31 January 2024
Accepted: 16 May 2024
First Online: 20 June 2024
Conflict of interest
: C. Grimm Consultant: AstraZeneca, Celgene, Clovis, Eisai, GSK, MSD, PharmaMar, Roche, Vifor Pharma, Sandoz. Speaker: Amgen, AstraZeneca, Eisai, GSK, MSD, PharmaMar, Roche. Direct research funding: AstraZeneca, Meda Pharma, Roche Diagnostics. Travel/meeting support: AstraZeneca, GSK, PharmaMar, Roche, Roche Diagnostics. M. Postl, T. Bartl and M. Danisch declare that they have no competing interests.